ArticleActa pharmacologica Sinica2018
Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
Article in Acta pharmacologica Sinica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Pooled it
- Efficacy of Anlotinib in Treating Progressive Glioblastoma: Insights From a Single-Center Study.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Anlotinib in cancer therapy: mechanisms of action, clinical applications, and future perspectives.Cancer chemotherapy and pharmacology · 2025Review
- Off-label use of anlotinib in malignancies' treatment: efficacy and management of adverse reactions.Pharmacological reports : PR · 2025Review
- Circulating metabolites of Borneolum syntheticum (Bingpian) ameliorate atherosclerosis in ApoEActa pharmacologica Sinica · 2025Article
- Anlotinib inhibits cervical cancer cell proliferation and invasion by suppressing cytokine secretion in activated cancer-associated fibroblasts.Frontiers in oncology · 2024Article
- Prediction of Pharmacokinetic Drug-Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling.Drug design, development and therapy · 2024Article
- Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report.International journal of women's health · 2024Article
- Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis.Frontiers in oncology · 2024Article
- Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-small cell lung cancer: a retrospective cohort study.Journal of thoracic disease · 2023Article
- Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial.EClinicalMedicine · 2023Article
- Cross-species comparison in nonclinical pharmacokinetics of lenvatinib by a simple HPLC with ultraviolet detection.Scientific reports · 2023Article
- Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer.JTO clinical and research reports · 2023Article
- Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib.Drug design, development and therapy · 2023Review
- Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer.Frontiers in oncology · 2023Article
- Gross perianal embryonal rhabdomyosarcoma with severe multiple bone metastases throughout the body: a case report.The Journal of international medical research · 2022Article
- Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer.Frontiers in pharmacology · 2022Article
- Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer.Frontiers in pharmacology · 2022Article
- Design, Synthesis, and Anticancer Activity Studies of Novel Quinoline-Chalcone Derivatives.Molecules (Basel, Switzerland) · 2021Article
- Anti-Angiogenic Therapy: Albumin-Binding Proteins Could Mediate Mechanisms Underlying the Accumulation of Small Molecule Receptor Tyrosine Kinase Inhibitors in Normal Tissues with Potential Harmful Effects on Health.Diseases (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anlotinib is a new oral tyrosine kinase inhibitor; this study was designed to characterize its pharmacokinetics and disposition. Anlotinib was evaluated in rats, tumor-bearing mice, and dogs and also assessed in vitro to characterize its pharmacokinetics and disposition and drug interaction potential. Samples were analyzed by liquid chromatography/mass spectrometry. Anlotinib, having good membrane permeability, was rapidly absorbed with oral bioavailability of 28%-58% in rats and 41%-77% in dogs. Terminal half-life of anlotinib in dogs (22.8±11.0 h) was longer than that in rats (5.1±1.6 h). This difference appeared to be mainly associated with an interspecies difference in total plasma clearance (rats, 5.35±1.31 L·h
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.